Solvay celebrates Medicine Nobel Prize winner Katalin Karikó
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
Good momentum in commercial CDMO business
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Supply readiness follows months of manufacturing to ensure timely and ample supply
Pfizer is likely to show GSK significant competition
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated